Adial Pharmaceuticals (NASDAQ:ADIL) Lowered to Hold at ValuEngine

Share on StockTwits

ValuEngine downgraded shares of Adial Pharmaceuticals (NASDAQ:ADIL) from a buy rating to a hold rating in a research note released on Friday, ValuEngine reports.

NASDAQ:ADIL opened at $1.45 on Friday. Adial Pharmaceuticals has a fifty-two week low of $1.34 and a fifty-two week high of $9.44. The firm’s 50 day moving average is $1.53 and its two-hundred day moving average is $1.74.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis.

Recommended Story: Why Invest in High-Yield Dividend Stocks?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.